Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis

被引:49
作者
Barlesi, Fabrice
Tummino, Celine
Tasei, Anne-Marie
Astoul, Philippe
机构
[1] Univ Mediterranee, Hop St Marguerite, Assistance Publ Hop Marseille, Resp Dis Div,Dept Thorac Oncol,Fac Med, F-13274 Marseille 09, France
[2] Univ Mediterranee, Hop St Marguerite, Assistance Publ Hop Marseille, Fac Med,Dept Pathol, F-13274 Marseille, France
关键词
lung cancer; chemotherapy; pemetrexed; side-effect; radiation therapy; radiation recall dermatitis; cutaneous; skin toxicity;
D O I
10.1016/j.lungcan.2006.06.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiation recall dermatitis is characterized by an inflammatory reaction within a previously irradiated volume after administration of a drug. Antineoplastic drugs have mainly been involved in radiation recall reactions. This phenomenon is well known but poorly understood. Many hypotheses as stem-cell depletion in the radiotherapy field, heritable mutations within surviving stem cells, local vascular changes as welt as a drug hypersensitivity reaction have been proposed to explain these reactions. In this report, we describe a non-small cell lung cancer patient treated with a carboplatin plus gemcitabine combination chemotherapy as first line followed by pemetrexed as second line therapy. Twenty-five years ago, she completed radiation therapy for breast cancer. Three days after the first cycle of pemetrexed, she presented with a radiation recall dermatitis. As EGFR-staining was negative, we rechallenged the patient with pemetrexed. Unfortunately, although less intense, we faced a recurrence of the skin reaction and pemetrexed was no longer continued. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:423 / 425
页数:3
相关论文
共 10 条
[1]   Radiation recall:: A well recognized but neglected phenomenon [J].
Azria, D ;
Magné, N ;
Zouhair, A ;
Castadot, P ;
Culine, S ;
Ychou, M ;
Stupp, R ;
Van Houtte, P ;
Dubois, JB ;
Ozsahin, M .
CANCER TREATMENT REVIEWS, 2005, 31 (07) :555-570
[2]   Case 3. Photo therapy recall with gemcitabine following ultraviolet B treatment [J].
Badger, J ;
Uzieblo, A ;
Srinivas, S ;
Kang, SW .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :7224-7225
[3]   Second-line treatment for advanced non-small cell lung cancer:: A systematic review [J].
Barlési, F ;
Jacot, W ;
Astoul, P ;
Pujol, JL .
LUNG CANCER, 2006, 51 (02) :159-172
[4]   Interaction of pemetrexed disodium (Alimta, multitargeted antifolate) and irradiation in vitro [J].
Bischof, M ;
Weber, KJ ;
Blatter, J ;
Wannenmacher, M ;
Latz, D .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (05) :1381-1388
[5]   Diagnosis in oncology - Side effects of chemotherapy - Case 1. Radiation recall dermatitis from gemcitabine [J].
Burstein, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :693-694
[6]   Characterizing the phenomenon of radiation recall dermatitis [J].
Camidge, R ;
Price, A .
RADIOTHERAPY AND ONCOLOGY, 2001, 59 (03) :237-245
[7]   Radiation recall reaction following gemcitabine [J].
Fogarty, G ;
Ball, D ;
Rischin, D .
LUNG CANCER, 2001, 33 (2-3) :299-302
[8]   Radiation recall dermatitis with pemetrexed [J].
Hureaux, J ;
Le Guen, Y ;
Tuchais, C ;
Savary, L ;
Urban, T .
LUNG CANCER, 2005, 50 (02) :255-258
[9]   Challenges in oncology - Case 2. Radiation recall associated with docetaxel [J].
Morkas, M ;
Fleming, D ;
Hahl, M .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :867-869
[10]  
Seiwert TY, 2005, J CLIN ONCOL, V23, p635S